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This study describes a novel form of severe fatal Protein
Losing Enteropathy caused by a nonsense mutation in Plas-
malemma Vesicle Associated Protein (PLVAP) gene resulting
in loss of PLVAP mRNA and protein expression of fenestrae
diaphragms and compromised endothelial barrier function.
BACKGROUND & AIMS: Severe intestinal diseases observed in
very young children are often the result of monogenic defects.
We used whole-exome sequencing (WES) to examine genetics
in a patient with a distinct severe form of protein-losing
enteropathy (PLE) characterized by hypoproteinemia, hypo-
albuminemia, and hypertriglyceridemia.
METHODS: WES was performed at the Centre for Applied
Genomics, Hospital for Sick Children, Toronto, Canada, and
exome library preparation was performed with the Ion Torrent
AmpliSeq RDY Exome Kit. Functional studies were based on the
identiﬁed mutation.
RESULTS: Using WES we identiﬁed a homozygous nonsense
mutation (1072C>T; p.Arg358*) in the PLVAP (plasmalemma
vesicle-associated protein) gene in an infant from consanguin-
eous parents who died at 5 months of age of severe PLE.
Functional studies determined that the mutated PLVAP mRNA
and protein were not expressed in the patient biopsy tissues,
presumably secondary to nonsense-mediated mRNA decay.
Pathological analysis showed that the loss of PLVAP resulted in
disruption of endothelial fenestrated diaphragms.
CONCLUSIONS: The PLVAP p.Arg358* mutation resulted in the
loss of PLVAP expression with subsequent deletion of the
diaphragms of endothelial fenestrae, which led to plasma pro-
tein extravasation, PLE, and ultimately death. (Cell Mol Gas-
troenterol Hepatol 2015;1:381–394; http://dx.doi.org/10.1016/
j.jcmgh.2015.05.001)Keywords: Endothelium; Fenestrae; Hypertriglyceridemia;
Hypoalbuminemia; Hypoproteinemia; Very Early Onset In-
ﬂammatory Bowel Disease; Monogenic Diseases; Protein-Losing
Enteropathy; Whole-Exome Sequencing.
rotein-losing enteropathy (PLE) is characterized byPexcessive loss of protein often due to the disruption of
the integrity of the intestinalmucosalmembrane or dilatation
of the intestinal lymphatic system. Two broad categories of
PLE have been described: mucosal injury causing the exces-
sive losses observed in inﬂammatory bowel disease (IBD)
and intestinal infections, and abnormalities of the lymphatic
system observed in primary intestinal lymphangiectasia.1,2
The latter encompasses the group of patients who present
with hypoalbuminemia, edema, and dilatation of the lym-
phatics of the enteric system of unclear etiology.
Recently there has been growing interest into the genetic
causes of severe intestinal phenotypes.3 For example, a novel
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tions in TTC7A was recently reported.4 However, in many
infants with severe intestinal disease, including PLE, the
causative genetic defects have yet to be identiﬁed.3 Here we
use whole-exome sequencing (WES) to identify a nonsense
mutation in the plasmalemma vesicle-associated protein
(PLVAP) gene that results in a distinct severe form of PLE
characterized by hypoproteinemia, hypoalbuminemia, and
hypertriglyceridemia. The human form of PLVAP deﬁciency
is nearly identical to that observed in Plvap knockout mice,5
demonstrating the critical role of PLVAP in endothelial bar-
rier function and intestinal homeostasis.
Materials and Methods
Patients
All experiments were performed with the approval of the
research ethics board at the Hospital for Sick Children.
Informed consent to participate in research was obtained. A
copy of the consent is available on the website of the Inter-
National Early Onset Paediatric IBD Cohort Study (NEOPICS)
at http://www.neopics.org/NEOPICS_Documents.html.
Samples from our patient with the PLVAP p.Arg358*
mutation were obtained on two occasions during endoscopic
investigation for severe PLE. Control samples from the du-
odenum or colon were obtained from patients who were
undergoing evaluation of gastrointestinal symptoms, among
whom the endoscopic, histologic, and follow-up clinical im-
pressions were normal. A case of congenital tufting enter-
opathy as well as microvillus inclusion disease initially
presenting with PLE were assigned as duodenal disease
controls. Biopsies from a patient with IBD with inﬂamed
areas in the colon served as a colonic disease control.
Next-Generation Sequencing
WES was performed at the Centre for Applied Genomics,
Hospital for Sick Children, Toronto, Canada. The exome
library preparation was performed using the Ion Torrent
AmpliSeq RDY Exome Kit (Life Technologies, Carlsbad, CA)
following the manufacturer’s recommended protocol. In
brief, 100 ng of DNA quantiﬁed by Qubit DNA HS or BR
assay (Life Technologies) was used in the target ampliﬁca-
tion under the following conditions: 99C for 2 minutes,Table 1.Plasmalemma Vesicle Associated Protein (PLVAP) Con
PLVAP
Construct
Start
PLVAP
aa #
End
PLVAP
aa #
Protein
Length (aa)
Protein M
Weight
FL-3xHA 1 442 442 50.5
389-3xHA 1 389 389 44.9
357-3xHA 1 357 357 41.1
R358* 1 357 357 41.1
348-3xHA 1 348 348 40.0
307-3xHA 1 307 307 35.4
266-3xHA 1 266 266 30.7
225-3xHA 1 225 225 25.0followed by 10 cycles at 95C for 15 seconds and 60C for
16 minutes, and a ﬁnal hold at 10C. Incorporated primers
sequences were partially digested using a proprietary
method. Ion Torrent Proton adapters were ligated to the
amplicons at 22C for 30 minutes followed by 72C for 10
minutes, and the library was puriﬁed with Agencourt
Ampure XT beads (Agencourt Bioscience, Beverly, MA).
Libraries were quantiﬁed by quantitative polymerase chain
reaction (PCR) and 7pM were used for sequencing on an Ion
Torrent Proton Sequencer using a PI chip V2 following the
manufacturer’s protocol. All data were aligned to the hg19/
GRCh37 reference genome and were quality trimmed via
Ion Torrent Suite version 4.2 (Life Technologies).
Next-Generation Sequencing Data Analysis. SNP and
Variation Suite version 8.1 (Golden Helix, Bozeman, MT) and
VarSeq Version 1.1 (Golden Helix) were used. After
importing the variant call ﬁles of each member of the family
trio (patient and parents), the variants were organized by
pedigree. Using the 1000 genomes Variant Frequencies
(phase 1), the Exome Aggregation Consortium Variant Fre-
quency database version 0.3 (Cambridge, MA), and the
NHLBI Exome Sequencing Project (https://esp.gs.
washington.edu/drupal/) V2 Exome Variant Frequencies,
rare variants (minor allele frequency <1%) were ﬁltered.
Variants were then classiﬁed according to whether they
were deemed to be coding. Nonsynonymous and unclassi-
ﬁed variants were then scored using the database for non-
synonymous functional predictions (dbNSFP 2.8),6,7 ﬁltering
out variants found to have no damaging score (Polyphen2,
SIFT, MutationTaster, MutationAssessor, FATHMM). As well,
dbNSFP scores variants with conservation scores (PhyloP
and GERPþþ).
Sanger Sequencing Validation. Sanger sequencing was
performed in the patient and his parents to validate the
mutation identiﬁed by WES (c.1072C>T; p.Arg358*). The
following primers were used to sequence exons 2 and 3:
forward AGCAAGTGTGAGATCAGCCT, and reverse
GGCCAACATAGTGAAACCCC.Constructs
The constructs generated are summarized here and in
Table 1. All PLVAP constructs were cloned into the EcoRIstructs Generated and Expected Characteristics
olecular
(kDa)
Protein þ N-
Glycosylation
(10 kDa)
3xHA
(kDa)
Monomer
(kDa)
Dimer
(kDa)
9 60.59 3.50 64.09 128.18
1 54.91 3.50 58.41 116.82
6 51.16 3.50 54.66 109.32
6 51.16 51.16 102.32
0 50.00 3.50 53.50 107.00
8 45.48 3.50 48.98 97.96
8 40.78 3.50 44.28 88.56
0 35.00 3.50 38.50 77.00
July 2015 PLVAP Mutations and PLE 383and SalI sites of pIRES-hrGFP2a bicistronic vector (Agilent
Technologies, San Diego, CA), allowing for expression of the
target construct and humanized Renilla green ﬂuorescent
protein (hrGFP). Two constructs encoding for the amino
acids 1–357 of human PLVAP were generated as a non-
tagged version (labeled PLVAP R358*) or fused in frame
with a string of three human inﬂuenza hemagglutinin (HA)
epitopes (labeled PLVAP 357-3xHA). The inserts were
ampliﬁed by PCR using Pfu polymerase (Agilent Technolo-
gies) and a previously reported8 full-length PLVAP (labeled
PLVAP FL-3xHA) construct as a template. The following
primers were used: sense 50TGAATTCAAATGGGTCTGG
CCATGGAGCAC30 and antisense: 50AAAAGTCGACTGCAGGTG
TCCAGGGCTGAGTTTC30 for PLVAP 389-3xHA; 50AAA
AGTCGACCTTCCTTCCGCAGCACCGC30 for PLVAP 357-3xHA;
50AAAAGTCGACTCATTCCTTCCGCAGCACCGC30 for PLVAP
R358*; 50AAAAGTCGACCCAGCGCTAGCTGGGTCTGCC30 for
PLVAP 348-3xHA; 50AAAAGTCGACTCTGGCGTTGGAGGT
CTGAG30 for PLVAP 307-3xHA; 50AAAAGTCGACAGGCCAATT
CCGAGCCCAG30 for PLVAP 266-3xHA; and 50AAAAGTCGA
CCGCAGAGGGCTTGCACCTTTTG30 for PLVAP 225-3xHA.
The PCR products and vector were digested with EcoRI
and SalI (New England Biolabs, Ipswich, MA), gel puriﬁed,
ligated using DNA ligase (Roche Applied Science, Indian-
apolis, IN), introduced in TOP10 Escherichia coli and
selected on agar plates containing 100 mg/mL ampicillin.
Positive clones conﬁrmed by sequencing and restriction
digestion were ampliﬁed using QiaPrep Endo-free columns
(Qiagen, Germantown, MD).
Antibodies
Mouse anti-human PLVAP mAb9 (clone PAL-E, cat. no.
ab8086), monoclonal antibody PAL-E speciﬁc for endothe-
lium, and mouse anti-human Plvap mAb Clone 174/210 were
purchased from Abcam (Cambridge, MA). Hybridoma cells
secreting PAL-E mAb was obtained from M. Kahn (University
of Pennsylvania) and was used to produce PAL-E mAb by
BioXCell (Lebanon, NH). Anti-HA mAb clone HA.11 was used
(Covance, Princeton, NJ). Chicken anti-human PV1C pAb was
previously described elsewhere.8 Goat anti-mouse IgG-HRP
was obtained from Biodesign (Saco, ME), rabbit anti-chicken
IgY-HRP was obtained from Sigma-Aldrich (St. Louis, MO),
and goat anti-mouse IgG-AlexaFluor 647 was obtained from
Life Technologies (Eugene, OR).
Antibody Labeling With Fluorophores
Afﬁnity puriﬁed primary antibodies mouse anti-PLVAP
mAb clone PAL-E were labeled with Alexa 647 ﬂuo-
rophores (Life Technologies, Carlsbad, CA), as per the man-
ufacturer’s instructions. The antibody-ﬂuorophore conjugate
was quality controlled for conjugation efﬁciency by spec-
troscopy (Varian Cary 50 BIO; Agilent Technologies) and for
aggregation by dynamic light scattering (Malvern Zetasizer
Nano-ZS; Malvern Instruments, Malvern, United Kingdom).
Cells
The spontaneously immortalized endothelial cell line
EA.hy926 (CRL-2922; American Type Culture Collection,Manassas, VA) or human embryonic kidney 293T
(HEK293T) cells were used for transfection experiments.
Cells were cultured in Dulbecco’s modiﬁed Eagle’s medium
with 10% fetal bovine serum, and penicillin streptomycin.
Transfections
Equal numbers of cells were seeded at 70% conﬂuence
and cultured for 16 to 24 hours before transfection with
various constructs using Lipofectamine LTX (Life Technol-
ogies), as per the manufacturer’s instructions. Controls
consisted of nontransfected cells and cells transfected with
empty pIRES-hrGFP2a vector. In all experiments the trans-
fection efﬁciency was w10% for EA.hy926 cells and >80%
for HEK293T cells, as determined by ﬂow cytometry using
hrGFP ﬂuorescence as the reporter.
Western Blotting
Equal numbers of cells were seeded in six-well plates
(Thermo Fisher Scientiﬁc, Waltham, MA) at 70% conﬂuence
and cultured for 16–24 hours before transfection with
various constructs. At 72 hours after transfection, the cells
were rinsed (two times at room temperature) with
phosphate-buffered saline (PBS), solubilized directly in 200
mL of nonreducing Laemmli sample buffer for sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE), boiled for 10 minutes, and frozen at 20C. Twenty-
ﬁve ml of cell extracts were centrifuged, resolved on 4%–15%
SDS-PAGE using Criterion gels (Bio-Rad Laboratories, Her-
cules, CA), transferred to polyvinylidene ﬂuoride mem-
branes, and immunoblotted with anti-human PLVAP mAbs
clone 174/2 (2 mg/mL, overnight, 4C) or clone PAL-E (10
mg/mL, overnight, 4C) or with chicken anti-human PV1C
pAb (2 mg/mL, overnight, 4C) in 5% nonfat milk and 0.1%
Tween-20 in PBS. Secondary detection was performed by
incubations (30minutes at room temperature) with 1 mg/mL
goat anti-mouse IgG-HRP or rabbit anti-chicken IgG-HRP,
respectively, diluted in 5% nonfat milk and 0.1% Tween-20
in PBS. The signal was detected by chemiluminescence
(Thermo-Fisher Pierce, Rockford, IL) followed by imaging
using a G-Box gel imager (Syngene, Cambridge, United
Kingdom). Image data was exported as .TIFF format and was
processed using Adobe Photoshop CS6 (Adobe Systems, San
Jose, CA). The signal was inverted, and the contrast and
brightness were adjusted using the auto levels function.
Flow Cytometry
For ﬂow cytometry, equal numbers of cells were seeded
at 70% conﬂuence in 24-well plates, in duplicate, and
transfected the next day with various constructs. At 72
hours after transfection, the cells were labeled (37C, 30
minutes, CO2 incubator) while live and adherent with either
10 mg/mL PAL-E mAb or 1 mg/mL anti-HA mAb in full-
growth medium. Unbound primary antibody was washed
(three times at room temperature) in Dulbecco’s phosphate-
buffered saline (DPBS) with calcium and magnesium
(HyClone, Logan, UT) and cells were chilled (5 minutes,
10C) to arrest endocytosis. Cells were incubated (30 mi-
nutes, 10C) with 3-mg/mL goat anti-mouse IgG in ice-cold
384 Elkadri et al Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 42% bovine serum albumin (BSA) in DPBS. Excess antibody
was removed by washes (three times on ice) in DPBS
without calcium and magnesium, and the cells were non-
enzymatically dissociated from the plate using 200 mL of cell
dissociation solution (Sigma-Aldrich). The dissociation so-
lution was removed, and the cells were resuspended in 1%
BSA in PBS without calcium and magnesium, and the ﬂuo-
rescence was read on a FACSCalibur (BD Biosciences, San
Jose, CA) within the Dartmouth DartLab ﬂow cytometry core
facility. The ﬂow cytometry data was analyzed with either
FlowLogic (Inivai Technologies, Mentone, Australia) or
FlowJo (FlowJo LLC, Ashland, OR) software. The ﬁgures
were assembled in either Adobe Photoshop or Adobe
Illustrator CS6 software (Adobe Systems).
Confocal Microscopy on Transfected Cells
Cells were seeded at 50% conﬂuence on 1% gelatin-
coated eight-well Nunc Lab-Tek II Chambered Coverglass
cultureware (Thermo Fisher Scientiﬁc) and transfected with
PLVAP FL-3xHA, PLVAP 389-3xHA, PLVAP 357-3xHA,
PLVAP R358* constructs or empty pIRES-hrGFP2a vector as
control, as described earlier. At 72 hours after transfection,
live adherent cells were labeled as described earlier for ﬂow
cytometry with either 10 mg/mL PAL-E mAb or 1 mg/mL
anti-HA mAb, followed by Alexa 555-conjugated goat anti-
mouse IgG for secondary detection. After the last wash,
with the secondary antibody the cells were ﬁxed (30 mi-
nutes, room temperature) with 4% paraformaldehyde in
PBS, washed (three times, 5 minutes, room temperature) in
PBS, labeled (5 minutes, room temperature) with 300 nM
40,6-diamidino-2-phenylindole dihydrochloride (DAPI,
D1306; Life Technologies), and washed (three times, 5 mi-
nutes) in PBS. The cells were imaged while immersed in
PBS. Imaging was done on a Zeiss 510Meta confocal mi-
croscope (Carl Zeiss Light Microscopy, Göttingen, Germany)
equipped with appropriate lasers (405 nm, 488 nm, 532
nm) and ﬁlters, all within the Dartmouth Norris Cotton
Cancer Center microscopy facility. The acquired images
were processed for brightness and contrast and analyzed
using ImageJ (http://imagej.nih.gov/ij/), and the ﬁgures
were mounted using Adobe Photoshop and Adobe Illus-
trator CS6.
EA.hy926 Stable Cell Lines
The Zeocin resistance gene from bGal-Zeo vector (Invi-
trogen/Life Technologies, Carlsbad, CA) was inserted in the
vectors encoding for the human PLVAP FL-3xHA, PLVAP
357-3xHA, and PLVAP R358* constructs described earlier.
The Zeocin resistance gene containing constructs was line-
arized and used to transfect EA.hy926 cells using Lipofect-
amine LTX (Invitrogen). Twenty-four hours after
transfection, the cells were switched to selection medium
[growth medium containing 40 mg/mL Zeocin (Invitrogen)]
and were under continuous selection for 4 weeks when the
cells were sorted on double hrGFP and anti-PV1 PAL-E mAb
positivity, using a FACSAria sorter (BD Biosciences). Mixed
clonal populations were further used for determination of
diaphragm formation by electron microscopy.Electron Microscopy
Patient duodenal biopsy tissue was ﬁxed (1 hour, room
temperature) by immersion in a ﬁxative consisting of 2%
glutaraldehyde and 3% paraformaldehyde in sodium caco-
dylate buffer, pH 7.2, and was further processed (1 hour, on
ice, in the dark) through 1% OsO4 postﬁxation, incubated (1
hour, room temperature, in dark) in 2% uranyl acetate,
dehydrated, and embedded in LX-112 resin (Ladd Research
Industries, Williston, VT). We obtained 30-nm-thick sections
by using a Leica EM UC6 microtome and an ultrasonic dia-
mond knife (Electron Microscopy Supplies/Diasum, Hat-
ﬁeld, PA), and they were examined and recorded under a
JEOL 1010 electron microscope (JEOL USA, Peabody, MA)
using a bottom-mount AMT camera (Advanced Microscopy
Techniques, Woburn, MA), within Dartmouth College elec-
tron microscopy facility.
Histologic Stains
Parafﬁn-embedded tissue sections were deparafﬁnized
using xylene and afterward were dehydrated with graded
ethanols. Next, slides were stained for 5 minutes with H&E
(Thermo Fisher Scientiﬁc). After dehydration of the tissue,
sections were mounted with Entellan mounting medium
(EMD Millipore, Billerica, MA). For periodic acid–Schiff
(PAS) cytochemistry, dehydrated sections were incubated in
0.5% periodic acid solution (Sigma-Aldrich) for 15 minutes
at room temperature. Afterward the tissue was washed
twice for 2 minutes with deionized water and incubated for
5 minutes in Schiff’s reagent solution (Sigma-Aldrich) in
darkness. Next, the sections were washed for 5 minutes at
room temperature and counterstained with hematoxylin
solution (Thermo Fisher Scientiﬁc). Finally, the slides were
rehydrated and mounted with Entellan. Photomicrographs
were taken using a Leica Inverted Light Microscope and
adapted for brightness, contrast, and pixel size using Adobe
Photoshop CS5 version 12.0 or Adobe Photoshop Illustrator
CS6.
Immunoﬂuorescence on Biopsy Samples
Intestinal biopsy samples from both the patient and
controls were ﬁxed either with 10% formaldehyde without
methanol and embedded in parafﬁn or directly processed
with O.C.T (Optimal Cutting Temperature) Compound (Tis-
sue-Tek; Sakura Finetek USA, Torrance, CA) for frozen sec-
tions. For parafﬁn-embedded sections, parafﬁn was
removed using xylene and afterward rehydrated with
different percentages of ethanol. An antigen retrieval step
was performed with high-pressure cooking with 1 mM
EDTA (ethylenediaminetetraacetic acid) at pH 9.0 with
0.05% Tween 20. Frozen sections were ﬁxed with ice-cold
methanol at 20C for 5 minutes and shortly washed
with 1x PBS without calcium and magnesium. Afterward,
slides were blocked for 1 hour at room temperature with
5% BSA in 1x PBS without calcium and magnesium con-
taining 15% goat serum. Primary antibody incubation was
performed overnight at 4C. The next day, the stained slides
were washed 3 times for 10 minutes with 1x PBS without
calcium and magnesium. Secondary antibody incubation
Figure 1. Low-power light
and electron microscopy
showing edema and
absence of intestinal
structural defects in
PLVAP p.R358* mutation.
(A) H&E and PAS stain of
the duodenum from a
control patient (left) and the
PLVAP p.R358* patient
(right). H&E and PAS stains
show prominent interstitial
edema in the duodenum
(shown by the pale inter-
stitium in the villus area).
Scale bars: 200 mm. (B)
Transmission electron mi-
croscopy analysis of the
duodenum from a control
patient (left) and the PLVAP
p.R358* patient (right)
showing no abnormalities
within the ultrastructure of
the enterocyte epithelium.
Scale bars: 2 mm.
July 2015 PLVAP Mutations and PLE 385was performed at room temperature and in darkness for 1
hour, and the slides were washed afterward 3 times for 10
minutes in darkness. Next, nuclear counterstaining with
Hoechst 33342 Fluorescence Stain (Thermo Fisher Scienti-
ﬁc) was performed at a dilution of 1:15,000. Finally the
sections were mounted overnight with Vectorshield ﬂuo-
rescence mounting medium (Vector Laboratories, Burlin-
game, CA).
Rabbit-polyclonal anti-ZO1 (Abcam), mouse-monoclonal
anti-b-catenin (BD Transduction Laboratories/BD Bio-
sciences), mouse-monoclonal anti-PLVAP clone 174/2
(Abcam), and rabbit-polyclonal anti CD31 (Abcam), poly-
clonal-rabbit anti-EpCAM (Sigma), mouse-monoclonalanti-CD10 (Dako) and mouse-monoclonal anti-Foxp3 (Dako)
were used as primary antibodies in a dilution of 1:100.
Alexa 568 goat anti-rabbit (Life Technologies) and Alexa
488 goat-anti mouse (Life Technologies) served as second-
ary antibodies in a dilution of 1:500. Alexa 647-conjugated
anti-PLVAP clone PAL-E mouse monoclonal antibody
described earlier was used on methanol-ﬁxed frozen sec-
tions at a concentration of 10 mg/mL blocking solution.
Photomicrographs of immunostained sections were
taken with an Olympus IX81 inverted ﬂuorescence micro-
scope (Olympus USA, Center Valley, PA) equipped with a
Hamamatsu C9100-13 back-thinned EM-CCD camera
(Hamamatsu Photonics, Hamamatsu, Japan) and Yokogawa
Figure 2. Identiﬁcation of a PLVAP mutation in an infant with severe protein-losing enteropathy. (A) Pedigree. (B) Whole-
exome sequencing variant ﬁltration algorithm showing the variants identiﬁed in the patient and parents (listed in
Supplementary Table 2). (C) Domain, gene, and mRNA view. Gray arrows show glycosylation sites. The identiﬁed mutation
(red), coil-coiled regions (pink), transmembrane regions (black), and a proline-rich region (green) are noted.
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Electric, Musashino, Japan). Images were adjusted for
contrast and brightness using the Volocity version 6.1.1
software (PerkinElmer Life and Analytical Sciences, Wal-
tham, MA). Images were then mounted adapted using
Adobe Photoshop CS5 version 12.0 or Adobe Photoshop
Illustrator CS6.RNA Detection by In Situ Hybridization on
Biopsy Samples
RNA was detected in formalin-ﬁxed parafﬁn embedded
biopsy tissue sections (10 mm thick) from patient and
controls by in situ hybridization using human PLVAP
C1-RNAscope probes and RNAscope technology,11 as per
manufacturer’s instructions (Advanced Cell Diagnostics,
Hayward, CA). RNAscope detection was performed at the
Dartmouth Norris Cotton Cancer Center Pathology Trans-
lational Research Laboratory core facility.Results
Clinical History
Our patient was born at 36 weeks’ gestational age via
cesarean delivery to consanguineous parents of Afghan
descent. He presented to the Hospital for Sick Children at 8
days of life with secretory diarrhea, metabolic acidosis,
lethargy, poor feeding, and severe hyponatremia causing
seizures. He developed hematochezia on the day 9 of life. On
further examination, he was also found to have bilateral
colobomas, undescended testes, mildly dysplastic kidneys
bilaterally, low-set ears, and micrognathia.
Most notable on laboratory examination was his
consistently undetectable (<10 g/L) albumin that did not
respond to repeated infusions (19 g/L was the highest level
drawn during a continuous albumin infusion). However,
there was no evidence of proteinuria; he had normal urea,
creatinine, transaminases, cortisol, and urine electrolytes
levels. All immunoglobulins (IgG, IgA, IgE, and IgD) were
low or undetectable, except for IgM, which was normal. His
Figure 3. PLVAP p.R358* mutation causing loss of the diaphragms of endothelial fenestrae and caveolae and severely
decreased levels of mRNA and protein. (A) Electron micrographs of small intestinal biopsies from control patient (left panel)
and PLVAP p.R358* patient (right panel). Fenestrae and caveolae of the mutant endothelial cells do not have diaphragms
(arrows) whereas diaphragms are readily present in normal endothelial cells (*). Scale bars: 500 nm. (B) Electron micrographs of
PLVAP p.R358* patient duodenum biopsy, showing extracellular lipid droplets (black arrows). The image on the right is a higher
magniﬁcation of the indicated area in the left micrograph. Scale bars: left, 2 mm; right, 1 mm.
July 2015 PLVAP Mutations and PLE 387thyroid-stimulating hormone levels were was severely
elevated (31.1 mIU/L), and the free thyroxine level was
undetectable (<5.1 pmol/L). The lipid proﬁle analysis
showed a markedly elevated triglyceride level (4.3–10.3
mmol/L), with normal cholesterol and high-density lipo-
protein levels (Supplementary Table 1).
Over the next 2 months of life, he developed enteroviral
and rhinoviral upper respiratory tract infections. He
persistently had severe anasarca and was found to havevenous thrombosis in multiple locations. After developing a
Klebsiella oxytocia urinary tract infection, he developed
ascites and acute breathing difﬁculty, followed by pericar-
dial effusion that required a pericardial drain placement.
Shortly before he was 5 months old, he developed
coagulase-negative Staphylococcus aureus sepsis, resulting
in decompensation, multiorgan failure, and death at 136
days old. No postmortem examination was performed at the
family’s request.
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Because of the patient’s severe ongoing diarrhea, an
upper and lower endoscopy was performed at 2 months
and 3.5 months of age, which showed severely pale edem-
atous duodenum, edematous stomach, and normal colon.
The H&E and PAS stainings demonstrated prominent,
diffuse edema in the interstitium with an absence of
epithelial architectural distortions, signs of lym-
phangiectasia, or signs of acute inﬂammation (Figure 1A
and B). Immunohistochemical analysis showed normal
basolateral epithelial cell adhesion molecule (EpCAM) and
apical CD10 expression and localization patterns. No
apparent changes were seen in interstitial regulatory T cells
expressing forkhead box P3 (FOXP3) (Supplementary
Figure 1) Also, the tight junctions and adherens junctions
were normal (Supplementary Figure 2A and B). Trans-
mission electron microscopy (TEM) showed normal apical
brush border microvilli with no histopathologic features of
congenital tufting enteropathy, microvillus inclusion dis-
ease, or immune dysregulation, polyendocrinopathy, en-
teropathy, X-linked syndrome (see Figure 1B). The patient-
derived enteroids demonstrated normal growth and
morphology (data not shown).Genetic Analysis
WES of the patient and parents using the Ion Torrent
Proton platform (Figure 2A) identiﬁed 49,722 variants (see
Figure 2B). As the patient’s parents were consanguineous,
we focused on rare damaging homozygous variants, and we
identiﬁed 17 variants (Supplementary Table 2). Based on
known protein function, expression proﬁles, animal models,
and conservation scoring, this list was narrowed down to a
single candidate gene, PLVAP. The identiﬁed homozygous
mutation in exon 3 of PLVAP resulted in a premature stop
codon (c.1072C>T; p.Arg358*) (see Figure 2C). The PLVAP
c.1072C>T mutation is extremely rare with only one het-
erozygote individual identiﬁed from over 121,000
sequenced (estimated minor allelic frequency of 8.2e-06;
http://exac.broadinstitute.org/variant/19-17476202-G-A).
PLVAP is a cationic, integral membrane glycoprotein that is
speciﬁcally expressed in endothelial cells.12 PLVAP forms
homodimers7 and plays a critical role in the formation of the
diaphragms of caveolae and fenestrae/transendothelial
channels.5,8,13 PLVAP-positive diaphragms of fenestrated
capillaries are essential for the maintenance of blood
composition.5,14Figure 4. (See previous page). PLVAP p.R358* mutation cau
caveolae and severely decreased levels of mRNA and protei
using RNAscope probes in duodenal biopsies from a normal con
(middle), and out PLVAP p.R358* patient (right). The general arc
bars: 100 mm. (B–D) Nuclei were stained with Hoechst (blue). T
(MVID) in B, CTE in E, and active colonic inﬂammatory bowel
immunoﬂuorescence with anti-PLVAP (clone PAL-E)-Alexa 64
sections of duodenal biopsies from normal control patient (lef
(right). Hoechst stains nuclei in blue. (C, D) Multiplex immunoﬂuo
(red) on formalin-ﬁxed, parafﬁn-embedded sections from norm
PLVAP p.R358* patient (right). Sections were obtained from duFunctional Analyses
To determine whether the diaphragms in the intestinal
fenestrated capillaries were disrupted in our patient, we
performed TEM with ultrathin (30-nm) sections of the small
intestinal biopsy. We observed an absence of diaphragms in
both the fenestrae and caveolae of the endothelial cells of
vessels in the intestinal biopsies (Figure 3A). Additionally,
general edema of the tissue (see Figure 1B, right panel) and
accumulation of lipid droplets in the interstitial area near
the endothelium were also observed (see Figure 3B). These
TEM ﬁndings are identical to those that have been described
in the Plvap knockout mice.5,15,16
The identiﬁed PLVAP 1072C>T p.Arg358* mutation is
predicted to introduce a premature stop codon and cause an
84 C-terminal amino acid truncation including part of the
PLVAP coil-coiled domain and the proline-rich region (see
Figure 2B). Because mRNAs with premature stop codons
can be targeted for degradation,17,18 we tested whether the
mutant PLVAP p.Arg358* mRNA and protein were
expressed in patient samples. Quantitative in situ hybridi-
zation with PLVAP-speciﬁc probes using RNAscope tech-
nology11,19 showed a drastic reduction in PLVAP mRNA
expression in the patient’s biopsy tissue (see Figure 4A,
right panel) whereas the signal was readily detected in bi-
opsies from normal and disease control patients (see
Figure 4A left and middle panel).
To conﬁrm these ﬁndings at the protein level, we ﬁrst
identiﬁed an antibody capable of detecting the truncated
PLVAP p.Arg358* protein. Using a battery of PLVAP trun-
cation mutants (Figure 5A) and previously characterized
anti-human PLVAP antibodies directed against its extracel-
lular domain (anti-PV1C pAb,8 clone 174/2,10 clone
PAL-E9,10), we determined that the anti-PLVAP mAb clone
PAL-E recognized an epitope between PLVAP amino acids
225–307 (data not shown) and thus was able to detect the
PLVAP p.Arg358* protein (see Figure 5B, top panel)
whereas clone 174/2 did not because it recognized an
epitope situated between amino acids 358–389 (see
Figure 5B, middle panel). As previously reported elsewhere,
PAL-E has a much higher afﬁnity for the dimeric form of the
PLVAP FL,9,10 which we found to be also true for PLVAP
truncation mutants (see Figure 5B, top panel). As expected,
anti-hPV1C pAb raised against the last 12 amino acids of
human PLVAP recognized only full-length PLVAP (see
Figure 5B, bottom panel).
To shore up the RNA data, we performed immunoﬂuo-
rescence with anti-PLVAP clone PAL-E directly conjugatedsing loss of the diaphragms of endothelial fenestrae and
n. (A) Detection of human PLVAP mRNA (blue-green staining)
trol patient (left), a congenital tufting enteropathy (CTE) patient
hitecture of the tissue is revealed by H&E counterstain. Scale
he disease controls used are microvillous inclusion disease
disease (IBD) in F. Scale bars (B–D): 100 mm. (B) Multiplex
7 (purple) and anti-CD31 (yellow) on methanol-ﬁxed frozen
t), control MVD patient (middle), and PLVAP p.R358* patient
rescence with anti-PLVAP (clone 174/2) (green) and anti-CD31
al control patient (left), control disease patient (middle), and
odenum (C) and colon (D) biopsies.
Figure 5. Functional studies of mutated forms of PLVAP. (A) Schematic constructs of various truncation mutations
generated. CC, coiled coil domain; 3xHA, trio tandem of HA epitopes; N-Glyc, N-glycosylation; PRR, proline rich region; TM,
transmembrane region. Downward orange lines mark the position of cysteines. (B) PLVAP R358* forms homodimers detected
by the anti-PLVAP mAb clone PAL-E. Immunoblotting analysis of 10% (top) or 4%–20% (middle and bottom) SDS-PAGE
resolved lysates of Ea.hy926 cells transfected with empty vector (EV) or with human PLVAP full length-3xHA (FL), human
PLVAP 1-389-3xHA (389), human PLVAP 1-357-3xHA (357-3xHA), or human PLVAP R358* truncation constructs. The
membranes have been probed with three available anti-human PLVAP antibodies recognizing different epitopes: PAL-E,
mouse anti-human PLVAP mAb clone PAL-E (top panel); mouse anti-human PLVAP mAb clone 174/2 (top panel); and anti-
hPV1C, chicken anti-human PV1C pAb. Ea.hy926 are devoid of endogenous PLVAP, but bands of expected molecular
weight were readily detected by all three antibodies in PLVAP FL-3xHA transfected cell lysates in reducing (r, w63 kDa) and
nonreducing (n,w126 kDa) conditions (corresponding to PLVAP FL-3xHA monomers or homodimers, respectively). The only
antibody that recognized PLVAP R358* and PLVAP 357-3xHA was PAL-E. (C) PLVAP R358* is N-glycosylated. Immuno-
blotting with PAL-E (top) or anti-HA mAb (bottom) of total cellular proteins from Ea.hy926 endothelial cells expressing PLVAP
truncation constructs treated (þ) or not () with PNGase F to remove N-glycans. The proteins were resolved by nonreducing
8% and reducing 4%–20% SDS-PAGE, respectively. Controls consisted of nontransfected (NT) or empty vector (EV) trans-
fected Ea.hy926 cells. The PAL-E antibody recognized bands of an appropriate size corresponding to the glycosylated and
deglycosylated forms of PLVAP FL-3xHA and -389-3XHA and R358* truncations constructs. (D) Immunoblotting with mouse
anti-HA mAb of total cellular proteins from endothelial cells expressing PLVAP truncation constructs treated (þ) or not () with
PNGase F to remove N-glycans resolved by reducing 8% SDS-PAGE. A w15 kDA drop was detected in 357-3xHA upon
PNGase F treatment (þ).
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from secondary antibody detection) and anti-CD31 anti-
bodies as a marker for endothelial cells.20 In concordancewith the RNAscope results, PLVAP protein expression was
drastically reduced in the patient’s biopsy tissue (see
Figure 4B–D and Supplementary Figure 2C and D).
Figure 6. PLVAP R358* trafﬁcked to the plasma membrane of endothelial cells. (A) Confocal microscopy demonstrating
the expression of PLVAP R358* on the surface of live endothelial cells. Live transfected cells were labeled with PAL-E mAb
followed by goat anti-mouse IgG-AlexaFluor 647 (red). The cells were transfected with bicistronic vectors encoding for full-
length PLVAP-3xHA (FL), PLVAP 389-3xHA (1-389), PLVAP R358* (R358*), or empty vector (EV). Transfected cells were
detected by hrGFP ﬂuorescence (green). Scale bars: 50 mm. (B) Flow cytometric analysis of Ea.hy962 cells transfected with
full-length PLVAP (FL-HA) (pink trace), PLVAP R358* (R358*) (orange trace), and PLVAP 357-3xHA (357 HA) (green trace).
Controls consisted of nontransfected Ea.hy962 cells (black trace) or Ea.hy962 cells transfected with empty vector (EV) (grey
trace). PLVAP constructs were expressed from bicistronic vectors also encoding for hrGFP as described in Materials and
Methods. Left: Gating on humanized Renilla green ﬂuorescent protein (hrGFP)-positive cells. Right: PAL-E mAb signal in
hrGFP-positive cells. (C) Flow cytometric analysis of Ea.hy962 cells transfected with full-length PLVAP (FL-3xHA), PLVAP
R358* (R358*), and PLVAP 357*-3xHA (1–357 HA) (green trace). Controls consisted of nontransfected Ea.hy962 cells (black
trace) or Ea.hy962 cells transfected with EV (grey trace). PLVAP constructs were expressed from bicistronic vectors also
encoding for hrGFP. Cells were labeled with either PAL-E mAb (two left columns) or with anti-HA mAb (two right columns). Left:
Gating on hrGFP-positive cells. Right: Gating on PAL-E or anti-HA mAb signal in hrGFP-positive cells.
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additional mechanisms contributing to PLVAP p.Arg358*
protein degradation such as failure to pass endoplasmic
reticulum quality control or defective trafﬁcking due to
improper folding and/or glycosylation.21 Our data demon-
strated that both PLVAP R358* and PLVAP 357-3xHA
were translated and readily expressed from a cDNA in
spontaneously immortalized human Ea.hy956 endothelial
cells (see Figure 5B) and other cell types in culture (not
shown). PLVAP R358* and PLVAP 357-3xHA proteins
formed homodimers, as shown by immunoblotting of pro-
teins resolved in reducing and nonreducing conditions with
either PAL-E or anti-HA mAbs (see Figure 5B–D). Both
constructs were N-glycosylated, demonstrating an apparent
drop in molecular weight of appropriate size (w10 kDa for
all monomers) upon treatment with PNGase F, anendoglycosidase puriﬁed from Flavobacterium meningo-
septicum that removes all N-linked glycans except those
containing core a1-3 fucose22 (see Figure 5C and D). And,
ﬁnally, both PLVAP R358* and PLVAP 357-3xHA constructs
were efﬁciently trafﬁcked to the plasma membrane, as
demonstrated by both confocal microscopy (Figure 6A) or
ﬂow cytometry (see Figure 6B and C) using PAL-E or anti-
HA antibodies on live nonpermeabilized cells.
These data show that the truncated PLVAP R358* dem-
onstrates similar biochemical and cell biological behavior to
full-length PLVAP, and improper folding or glycosylation is
not a likely cause for the lack of PLVAP p.Arg358* protein in
patient samples. Together, the data strongly suggest that
PLVAP 1072C>T p.Arg358* mutation results in a de facto
PLVAP knockout due to efﬁcient degradation of mutant
RNA.
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PLVAP encodes an endothelial speciﬁc type II integral
membrane protein forming homodimers thought to create
the radial ﬁbrils/spokes in the ring-and-spoke structure of
the diaphragms of endothelial fenestrae, transendothelial
channels, and caveolae.23 By this model, PLVAP C-termini
would form the center/hub of the diaphragm by protein-
protein interactions with as yet unknown partners23
(Figure 7). Interestingly, the clinical and pathological ﬁnd-
ings in our patient are nearly identical to the previously
described Plvap knockout mouse models where Plvap-
deﬁciency results in loss of diaphragms and a sieving
vascular leakage of plasma proteins characterized by
hypoproteinemia, edema, and hypertriglyceridemia with
extracellular lipid deposits.5,15,16
Electron microscopic observation of our patient’s biopsy
samples demonstrated a complete lack of diaphragms in the
fenestrae and caveolae of endothelial cells of all the capil-
laries in the duodenum villi we examined. Besides the
clinical presentation (as described herein), the histopatho-
logic and electron microscopic observations detected other
signs such as tissue edema, endothelial thickening, and
extracellular lipid deposition that were previously reported
in Plvap knockout mice.5,15,16 These data suggest that the
truncated mutant PLVAP was either not expressed or inca-
pable of forming diaphragms (see Figure 7).
The identiﬁed PLVAP 1072C>T p.Arg358* mutation
introduces a premature stop codon in exon 3 resulting in a
C-terminal truncation of 84aa if the mutant mRNA would be
stable and translated into protein. The location of the
premature stop codon on PLVAP exon 3 (the stop codon of
full-length PLVAP mRNA is on exon 6) at more than 100
nucleotides from the nearest exon-exon junction makes the
mutant PLVAP p.Arg358* mRNA a good candidate for
degradation via nonsense-mediated decay.17,18 These andFigure 7. Proposed effect of PLVAP R358* mutation on
endothelial fenestrae diaphragms. Expression of PLVAP
leads to the formation of diaphragms in fenestrae (top).
PLVAP R358* mutation results in the degradation of the vast
majority of mRNA possibly via nonsense mediated decay
(NMD), resulting in loss of PLVAP protein and failure in fe-
nestrae diaphragm formation (bottom). Plasma proteins such
as albumin (yellow) and immunoglobulins (blue) are subse-
quently lost due to absence of fenestrae.the electron microscopy data prompted us to test whether
the mutant mRNA and protein were expressed in the pa-
tient’s samples.
Using a robust quantitative in situ hybridization tech-
nology (RNAscope), we found that the patient’s intestinal
biopsy samples had drastically reduced PLVAP mRNA
signal. The decreased mRNA signal is likely not the result of
the hybridization mismatch between PLVAP RNAscope
probes and the single-nucleotide mutated mRNA, as RNA-
scope probes consist of 20 sets of individual 20-nucleotide
probes spanning approximately 1 kb of the target mRNA.
Our data show that this likely is not a technical artifact
from the degradation of RNA, as intestinal biopsies from
disease controls collected and processed by the same
stringent protocol showed a very robust signal. Moreover,
all four different biopsies (duodenum and colon at two time
points) from the patient showed a drastically decreased
PLVAP mRNA signal. Most compellingly, the decreased
expression of mutant mRNA was strongly supported by
data showing that PLVAP protein was not expressed in the
patient intestine biopsies, whereas clear PLVAP signal was
obtained in the endothelial cells of vessels in biopsies from
the normal and diseased controls. The lack of mutant
PLVAP p.Arg358* protein expression was not due to
problems in protein folding in the endoplasmic reticulum
and subsequent degradation, as PLVAP p.Arg358* formed
homodimers of expected molecular size. Additionally,
PLVAP p.Arg358* underwent N-glycosylation similar to the
normal full-length PLVAP, suggesting progression through
the Golgi apparatus, and was trafﬁcked correctly to the cell
surface when transiently or stably expressed in endothelial
cells or other mammalian cells. Thus, the identiﬁed muta-
tion results in a de facto PLVAP knockout likely due to
mRNA instability.
Here, we describe the ﬁrst human PLVAP mutation
resulting in a severe fatal sieving hypoproteinemia and
enteropathy. Deletion of fenestral diaphragms causes
leakage of plasma proteins into the interstitium of organs
provided with fenestrated capillaries (intestine, pancreas,
adrenals) and from there into the peritoneal cavity and
into the intestine lumen, but not in organs with contin-
uous endothelium (heart, muscle, and lung).10,12 In our
patient, a number of plasma proteins were severely
decreased, including albumin (65–70 kDa), IgA, D, G, and E
(150 kDa), ceruloplasmin (151 kDa), and thyroxine-
binding globulin (54 kDa); IgM (755 kDa) was normal as
a result of selected loss of proteins based on their size.
Therefore, the hypoproteinemia, hypoalbuminemia, and
hypertriglyceridemia observed in our patient occurred due
to loss of fenestral diaphragms in the intestine.5 In
contrast, the absence of PLVAP-positive fenestral
diaphragms in the liver sinusoids or glomerulus24 explains
the lack of proteinuria and the normal liver function found
in our patient.
The abnormal lipid composition in the described patient
resembled the lipid proﬁle found in the Plvap knockout
mice,5 although in general the severity of the changes was
less in our patient compared with the mouse model. High-
density lipoprotein-cholesterol concentrations were within
July 2015 PLVAP Mutations and PLE 393the reference values in our patient but were found to be
lower in the mouse model. Triglyceride concentrations were
up to 10-fold higher in our patient, but >20 fold higher
in the knockout mice compared with wild-type mice,
which does indicate a difference in metabolic disease
severity. Based on their ﬁndings of similar levels of gene
expression of apoB mRNA levels they suggested that the
hypertriglyceridemia was not related to an enhanced very-
low-density lipoprotein (VLDL) secretion. In support of
this hypothesis is the ﬁnding that in nutritionally induced
hypoproteinemia (ie, severe acute malnutrition) VLDL
secretion appears not to be affected.25 Plvap knockout mice
exhibited a very slow decrease of VLDL levels upon fasting,5
suggesting that hypertriglyceridemia was most likely due to
impaired lipoprotein lipase function, which is an essential
enzyme that hydrolyzes lipoprotein-bound triglycerides. In
addition, triglyceride-rich lipoprotein particles such as VLDL
(25–90 nm), chylomicrons (1000 nm), and chylomicron
remnants (30–50 nm) are larger than the molecular diam-
eter cutoff (w30 nm) resulting from a loss of diaphragms
and persistence of the capillary basement membrane. Un-
fortunately, we were unable to measure lipoprotein lipase
function in our affected patient to support the hypothesis
that hypertriglyceridemia is related to low levels of lipo-
protein lipase in loss of PLVAP in humans.
The pathogenesis of the hypoalbuminemia observed in
our PLVAP-deﬁciency patient was signiﬁcantly different from
the two broad categories that are commonly used to describe
PLE.1,2 Although our patient initially presented with bloody
diarrhea, there was no histologic evidence of mucosal injury
which causes the excessive protein losses observed in ul-
cerative colitis,26 Crohn’s disease,27 and TTC7A deﬁciency.4
We also did not identify any abnormalities of the lymphatic
system, which are observed in primary intestinal lym-
phangiectasia.28 In contrast to other congenital enteropathies
such as microvillus inclusion disease or congenital tufting
enteropathy, the primary defect was not harbored by intes-
tinal epithelial but by endothelial cells.29–32 Duodenal
enterocytes in our patient with PLVAP mutation showed
normal brush border morphology, indicating that the intes-
tinal barrier function was not primarily affected. Therefore,
the intractable secretory diarrhea observed in our PLVAP
patient was not caused by malabsorption due to defective
brush border but as a consequence of protein loss
and reduced colloid osmotic pressure due to leaky fenes-
trated capillaries in the intestine. The precise molecular
mechanism of epithelial barrier failure and resultant PLE are
not known.
In summary, we identiﬁed a homozygous nonsense
mutation in the PLVAP gene in our patient who developed
severe PLE, which was nearly identical to the phenotype
observed in the Plvap knockout mice. In both mice and
humans, the loss of functional PLVAP results in disruption of
fenestral diaphragms in the intestinal vasculature that is
characterized by hypoproteinemia, hypoalbuminemia,
hypertriglyceridemia, and premature death. Further work in
animals modeling the human PLVAP mutation should shed
light on the molecular mechanism of PLVAP down-
regulation as well as the molecular mechanisms resultingin epithelial barrier disruption, prompting interventional
strategies.References
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Supplementary
Figure 1. Immunohisto-
chemistry staining for
epithelial cell adhesion
molecule (EpCAM, A),
CD10 (B), and Foxp3 (C) in
duodenal biopsy samples
from the patient. Normal
expression and localiza-
tion of EpCAM, CD10, and
Foxp3 in the duodenum.
Scale bars: (A) 8 mm; (B, C)
100 mm.
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Supplementary Figure 2. (A) Immuno-
ﬂuorescence analysis of tight junc-
tions (ZO-1) and adherens junctions
(b-catenin) in the duodenum of control
patient, disease control patient, and
the study patient. A congenital tufting
enteropathy (CTE) case presenting as
protein-losing enteropathy (PLE) served
as a proper disease control for the small
intestine. Alexa 568 red stains ZO-1,
Alexa 488 b-catenin, and Hoechst
nuclei in blue. ZO-1 localizes subapical
and b-catenin basolateral in villus as well
as crypt enterocytes of control, CTE, and
study patient. Scale bar: 10 mm. (B)
Immunoﬂuorescence analysis of tight
junctions (ZO-1) and adherens junctions
(b-catenin) in the colon of control, dis-
ease control, and study patient. A patient
with inﬂammatory bowel disease (IBD)
with active disease (inﬂamed areas in the
colon) served as the disease control for
the colon. Alexa 568 red stains ZO-1,
Alexa 488 b-catenin, and Hoechst
nuclei in blue. ZO-1 localizes subapical
and b-catenin basolateral in villus as well
as crypt enterocytes of the control pa-
tient, the IBD case, and the study patient.
Scale bar: 10 mm. (C) Immunoﬂuores-
cence analysis of vessels in the duo-
denum of the control patient, the disease
control patient, and the study patient. A
CTE case presenting as PLE served as a
proper disease control for the small in-
testine. Alexa 568 red stains CD31
(vessel marker), Alexa 488 PLVAP, and
Hoechst nuclei in blue. CD31 marks the
vessel walls and colocalizes with PLVAP
in the control and CTE. In the patient the
vessels are stained by CD31, but in the
absence of PLVAP. Scale bar: 10 mm. (D)
Immunoﬂuorescence analysis of vessels
in the colon of control, disease control,
and the patient. A patient with IBD with
active disease (inﬂamed areas in the
colon) served as a disease control for the
colon. Alexa 568 red stains CD31 (vessel
marker), Alexa 488 PLVAP, and Hoechst
nuclei in blue. CD31 marks the vessel
walls and colocalizes with PLVAP in the
control and IBD cases. In the study pa-
tient, the vessels are stained by CD31,
but in the absence of PLVAP. Scale bar:
10 mm.
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Supplementary Figure 2. (continued).
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Supplementary Table 1.Clinical Laboratory Values
Age in
Days
TSH
(mIU/L)
Free T4
(pmol/L)
IgG
(g/L)
IgA
(g/L)
IgM
(g/L)
IgE
(g/L)
IgD
(g/L)
Total
Protein
(g/L)
Albumin
(g/L)
Conjugated
Bilirubin
(mmol/L)
Unconjugated
Bilirubin
(mmol/L)
ALT
(U/L)
AST
(U/L)
GGT
(U/L)
Cholesterol
(mmol/L)
HDL
(mmol/L)
Triglycerides
(mmol/L)
8 31.11 <5.1
9 <10 33 16 90
10 11
11 10
12 104.9 <5.1 11
13 10
14 108.9 <5.1 <10 0 0 28 13 71
15 <20 <10
16 <1.1 <0.1 0.3 <25 <26
21 1.35a 35 32 56
22 3.71a 12a
23 40 19 0 14
29 41 19 0 1
34 4.04a <20 <10 0 0 36 19
35 5.78a 11.9a 10 0 0 42 33
40 <10
42 3.8a 6a <10
47 <1.1 <0.1 0.2 <25 <10
50 0 0
51 4.68a 6.2a
55 <10
58 11.51a 9a <10 0 0 26 11 139
64 4.06a 8.3a 3.22 0.34 6.86
71 <10 11 3.84 0.39 4.37
75 0 0
82 1.03a 12.2a
84 <10
85 10
89 24 11 0 0 29 14
96 <20 <10 0 0 24 7
103 20 <10 0 0 24 8
110 0.85a 9.4a <20 <10 0 0 27 12
114 <10 0 0 23 11 223
116 <10
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Supplementary Table 1.Continued
Age in
Days
TSH
(mIU/L)
Free T4
(pmol/L)
IgG
(g/L)
IgA
(g/L)
IgM
(g/L)
IgE
(g/L)
IgD
(g/L)
Total
Protein
(g/L)
Albumin
(g/L)
Conjugated
Bilirubin
(mmol/L)
Unconjugated
Bilirubin
(mmol/L)
ALT
(U/L)
AST
(U/L)
GGT
(U/L)
Cholesterol
(mmol/L)
HDL
(mmol/L)
Triglycerides
(mmol/L)
117 <20 <10 0 0 27 12
119 11
123 <10 0 0 27 29
124 0.06a 8.4a <1.1 0.1 0.6 <25 23 10 0 0 25 15
128 <20 <10 0 0 21 17
128 <20 <10 0 0 22 44
133 <20 <10 0 0 20 82
134 0.6a 8.4a <20 <10 10.35
135 <20
136 0.44a 7.9a <10 0 0 42 26 290
ALT, alanine transaminase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transpeptidase; HDL, high-density lipoprotein; Ig, immunoglobulin; T4, thyroxine;
TSH, thyroid-stimulating hormone.
aInitiation of thyroxine therapy. Albumin above 10 g/L occurred when patient was on albumin infusion.
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